Novel Treatment Paradigms: Complement Inhibition in Antineutrophil Cytoplasmic Autoantibody Vasculitis
Bibliographic record
Abstract
A growing body of evidence has highlighted the critical role of complement activation-particularly through the alternative pathway-in the pathogenesis of antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Foundational insights first emerged from landmark mouse model studies, which have been further substantiated by findings in human ANCA vasculitis. In addition, measuring complement activation fragments in circulation and urine may correlate with disease activity and may serve as sensitive biomarkers for disease monitoring. C5a and C5a receptor engagement has been shown to be particularly important for mediating disease and has been a central therapeutic target. Avacopan is an oral small molecule C5a receptor antagonist approved as adjunctive therapy to standard treatments for severe active ANCA vasculitis. Studies have shown that avacopan can reduce disease activity, proteinuria, and glucocorticoid exposure; and may even allow for greater kidney recovery in patients with ANCA vasculitis and severe renal insufficiency. Additional therapies targeting various components of the complement cascade are under investigation or in development, generating considerable excitement for novel treatment strategies in ANCA vasculitis. This review discusses key clinical developments and summarizes pivotal clinical trials evaluating complement inhibition in ANCA vasculitis. Although early results suggest that complement inhibitors may offer more effective and safer alternatives to established therapies, there are limitations and barriers that prevent their more widespread use. Further research is needed to better understand their efficacy and long-term safety and to inform how to optimize their integration into treatment paradigms for ANCA vasculitis.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".